Drug Trial Radar · NCT03962855
Thromboxane Receptor Antagonist to Improve Endothelial Function
Last checked: Nov 19, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Sep 20, 2019
Primary completion
Nov 7, 2022
Study completion Nov 15, 2022
Sponsor
- Lead sponsor
- Jeffrey RadeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- American Heart Association; Cumberland Pharmaceuticals
- First posted
- May 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates whether addition of the thromboxane receptor antagonist to chronic aspirin therapy improves endothelial function and reduces non-platelet thromboxane generation in patients with established cardiovascular disease. Half of participants will receive ifetroban and the other half will receive matching placebo for the 4 week study period.
Conditions
- Cardiovascular Diseases
- Vascular Dilation
Interventions
Ifetroban SodiumDrug
Ifetroban sodium 250 mg capsule once daily for 4 weeks
PlaceboDrug
Placebo arm to match Ifetroban Sodium once daily for 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Reactive Hyperemia Index (RHI)Time frame: Baseline to 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Massachusetts Medical School
Worcester, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.